Three pharmaceutical companies are being investigated by the Competition Commission for suspected excessive pricing of their cancer drugs.
The three companies are generic drug maker Aspen Pharmacare, Roche and Pfizer.
Deputy commissioner at the Competition Commission, Hardin Ratshisusu, says affordability of cancer drugs is an imperative.
We have been looking into this matter and we have now settled to initiate an investigation into these three companies.— Hardin Ratshisusu, Deputy Commissioner
These are separate investigations but they all cut across the cancer drugs— Hardin Ratshisusu, Deputy Commissioner
According to Ratshisusu, Pfizer will be investigated for a particular drug that treats cancer, for Roche they will be probing for a drug that treats breast cancer and for Aspen, a drug that treats leukemia.
We have information that points to potential exploitation by these companies, their prices are extremely excessive.— Hardin Ratshisusu, Deputy Commissioner
The official investigation was initiated on Tuesday, says Ratshisusu.
To hear more about this investigation into these three pharmaceutical companies, listen below:
This article first appeared on CapeTalk : Three pharmaceutical companies probed for excessive pricing of cancer drugs